View More Recent Stories
-
Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
-
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
-
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
-
Applied DNA Sciences (APDN) Enters into Multi-Year Commercialization Agreement with Indus Group
-
Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability
-
Applied DNA Sciences (APDN): U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
-
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
-
Applied DNA Sciences (APDN) and Alphazyme (MRVI) Conclude Linea RNAP Manufacturing Scale-up Project
-
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
-
Applied DNA Sciences (APDN) Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
-
Applied DNA Sciences (APDN) Partners with GenXys Health Care Systems
-
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
-
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
-
Applied DNA Sciences (APDN) Receives Approval for TR8 Pharmacogenomic Testing Service from New York State Department of Health
-
Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
-
Applied DNA Sciences (APDN) PT Lowered to $1.50 at H.C. Wainwright
